Jian-Ping Zhang1,2,3, Anil K Malhotra4,5,6. 1. Department of Psychiatry, Hofstra Northwell School of Medicine, Hempstead, NY, USA. jzhang1@northwell.edu. 2. Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, 75-59 263rd Street, Glen Oaks, NY, 11004, USA. jzhang1@northwell.edu. 3. Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA. jzhang1@northwell.edu. 4. Department of Psychiatry, Hofstra Northwell School of Medicine, Hempstead, NY, USA. amalhotra@northwell.edu. 5. Division of Psychiatry Research, Zucker Hillside Hospital, Northwell Health, 75-59 263rd Street, Glen Oaks, NY, 11004, USA. amalhotra@northwell.edu. 6. Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA. amalhotra@northwell.edu.
Abstract
PURPOSE OF REVIEW: Pharmacogenomics (PGx) of antipsychotic drug response is an active area of research in the past few years. We reviewed recent PGx studies with an emphasis of development of new methodologies and new research directions. RECENT FINDINGS: Traditional candidate gene approach continues to generate evidence to support the associations of antipsychotic response with genes coding for drug targets such as DRD2. Genome-wide association studies have found a few novel genes that may be associated with drug efficacy and adverse events. Recent application of polygenic risk score makes it possible to combine many genetic variants to predict clinical response. Finally, epigenetic research including DNA methylation is emerging and promises new findings that potentially can be applied in clinical practice. New methodologies may advance PGx closer to clinical application. Multiple genes and epigenomic markers can be used in prediction of clinical phenotypes.
PURPOSE OF REVIEW: Pharmacogenomics (PGx) of antipsychotic drug response is an active area of research in the past few years. We reviewed recent PGx studies with an emphasis of development of new methodologies and new research directions. RECENT FINDINGS: Traditional candidate gene approach continues to generate evidence to support the associations of antipsychotic response with genes coding for drug targets such as DRD2. Genome-wide association studies have found a few novel genes that may be associated with drug efficacy and adverse events. Recent application of polygenic risk score makes it possible to combine many genetic variants to predict clinical response. Finally, epigenetic research including DNA methylation is emerging and promises new findings that potentially can be applied in clinical practice. New methodologies may advance PGx closer to clinical application. Multiple genes and epigenomic markers can be used in prediction of clinical phenotypes.
Authors: Douglas M Ruderfer; Alexander W Charney; Ben Readhead; Brian A Kidd; Anna K Kähler; Paul J Kenny; Michael J Keiser; Jennifer L Moran; Christina M Hultman; Stuart A Scott; Patrick F Sullivan; Shaun M Purcell; Joel T Dudley; Pamela Sklar Journal: Lancet Psychiatry Date: 2016-02-23 Impact factor: 27.083
Authors: Shaunna L Clark; Renan P Souza; Daniel E Adkins; Karolina Aberg; József Bukszár; Joseph L McClay; Patrick F Sullivan; Edwin J C G van den Oord Journal: Pharmacogenet Genomics Date: 2013-02 Impact factor: 2.089
Authors: René S Kahn; Iris E Sommer; Robin M Murray; Andreas Meyer-Lindenberg; Daniel R Weinberger; Tyrone D Cannon; Michael O'Donovan; Christoph U Correll; John M Kane; Jim van Os; Thomas R Insel Journal: Nat Rev Dis Primers Date: 2015-11-12 Impact factor: 52.329
Authors: Karolina A Aberg; Lin Y Xie; Joseph L McClay; Srilaxmi Nerella; Sarah Vunck; Sarah Snider; Patrick M Beardsley; Edwin J C G van den Oord Journal: Epigenomics Date: 2013-08 Impact factor: 4.778
Authors: Arturas Petronis; Irving I Gottesman; Peixiang Kan; James L Kennedy; Vincenzo S Basile; Andrew D Paterson; Violeta Popendikyte Journal: Schizophr Bull Date: 2003 Impact factor: 9.306
Authors: Adaikalavan Ramasamy; Daniah Trabzuni; Sebastian Guelfi; Vibin Varghese; Colin Smith; Robert Walker; Tisham De; Lachlan Coin; Rohan de Silva; Mark R Cookson; Andrew B Singleton; John Hardy; Mina Ryten; Michael E Weale Journal: Nat Neurosci Date: 2014-08-31 Impact factor: 24.884
Authors: Jaana Suvisaari; Outi Mantere; Jaakko Keinänen; Teemu Mäntylä; Eva Rikandi; Maija Lindgren; Tuula Kieseppä; Tuukka T Raij Journal: Front Psychiatry Date: 2018-11-13 Impact factor: 4.157